<?xml version="1.0" encoding="UTF-8"?>
<p id="Par53">Cell therapy (CT) with autologous bone marrow (BM)-derived or peripheral blood (PB)-derived vasculogenic cells has emerged as an alternative viable therapeutic option [
 <xref ref-type="bibr" rid="CR9">9</xref>, 
 <xref ref-type="bibr" rid="CR10">10</xref>]. Randomized controlled trials (RCT) as well as meta-analyses and pooled analyses have recognizably shown, in large cohorts of RA patients, that catheter-based intramyocardial injection of BM or PB-derived selected or unselected progenitors has the ability to improve symptoms, exercise capability and myocardial perfusion with durable effects [
 <xref ref-type="bibr" rid="CR11">11</xref>â€“
 <xref ref-type="bibr" rid="CR13">13</xref>].
</p>
